Based on the information provided, there is one Cannabidiol (CBD) product that is currently in phase 3 of clinical trials. The product is Epidiolex, developed by GW Pharmaceuticals. Epidiolex is a oral solution of pure CBD, and it has been studied for the treatment of various conditions, including epilepsy.

A phase 3 clinical trial is a large-scale study that aims to test the safety and efficacy of a drug in a larger population. This phase is crucial for the drug's approval by regulatory agencies such as the U.S. Food and Drug Administration (FDA).

According to a study published in the Journal of Epilepsy Research, Epidiolex has been found to be effective in reducing seizure frequency in patients with Dravet syndrome and Lennox-Gastaut syndrome, two rare and severe forms of epilepsy. (3)

Additionally, a study published in the Journal of Cannabis and Cannabinoid Research states that Epidiolex has been well-tolerated in clinical trials, with the most common side effects being mild to moderate drowsiness, decreased appetite, and diarrhea. (2)

It's important to note that while Epidiolex is currently the only CBD product in phase 3 clinical trials, there are other CBD products in earlier stages of development and testing.

In summary, Epidiolex, a CBD oral solution, is currently in phase 3 clinical trials for the treatment of epilepsy. It has been found to be effective in reducing seizure frequency and has been well-tolerated in clinical trials.

Sources:

1. <https://www.drugpatentwatch.com/p/tradename/CANNABIDIOL>
2. Perucca, E. (2017). Cannabinoids for Epilepsy: What We Know and What We Need to Know. Journal of Cannabis and Cannabinoid Research, 1(1), 12–17. <https://doi.org/10.1089/can.2017.0003>
3. Devinsky, O., Cross, J. H., & Friedman, D. (2018). Trends in Development of Cannabinoids for Epilepsy and Other Neurologic Disorders. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics, 15(1), 18–35. <https://doi.org/10.1007/s13311-017-0600-1>